AbbVie CSO Roopal Thakkar described bretisilocin, a DMT-related psychedelic for major depressive disorder acquired from Gilgamesh for $1.2 billion, as a 'breakthrough type therapy' due to its short hallucinatory period during Q4 earnings call.3
Phase 2 data from March 2025 showed nearly all 40 MDD patients achieved remission; additional Phase 2 data expected in 2026 to guide Phase 3 plans.3
J&J's Spravato sales reached $503 million in Q4 2025 (69% YoY growth) and $1.7 billion for the full year, boosting psychedelics market confidence.3
Bretisilocin Phase IIa trial reported 21.6-point MADRS reduction vs. 12.1 in control, well-tolerated.4
Analysts note Spravato's success paves way for other psychedelics like AbbVie's by building infrastructure and reimbursement.3
Sources:
3. https://www.biospace.com/drug-development/abbvie-cso-touts-breakthrough-type-therapy-psychedelic-as-j-js-spravato-keeps-growing
4. https://www.bioxconomy.com/partnering/abbvie-acquires-gilgamesh-s-psychedelic-in-1-2bn-depression-treatment-deal